Based in New Hampshire, USA, John is a 33-year veteran of the Medical Device industry. Ten of those years were spent in senior expatriate assignments. Before becoming President and CEO of GKC, he served as President and CEO of Monteris Medical Corporation. Prior to joining Monteris, John served as the Chief Commercialization Officer for BÂRRX Medical, and as President and CEO of Softscope Medical Technologies Inc., both of which were successfully acquired by strategic partners during his tenure. John has held positions as Vice President of Sales and Marketing for the Peripheral Vascular Division of ev3 Inc., Vice President and General Manager International for ACMI Corporation, and various management positions within Boston Scientific. John earned a B.A, Summa Cum Laude, from Long Island University and, prior to his commercial career, he served 7 years as a U.S. Marine Corps pilot.
John is a 25 year veteran of the medical device industry, having joined us from Honeywell Corporation where he was President of their Life Care Solutions division. John is an accomplished commercially-focused senior executive with deep operational, global and start-up leadership. He has successfully served in leadership positions with large, global, publicly-held businesses as well as early stage, venture backed start-ups. John has driven successful businesses to greater heights as well as turned around underperforming businesses and divisions of companies. Other notable positions were President and CEO of Motus Medical, President of NiTi Surgical Solutions (US) and Executive VP, Sales & Marketing for Scandius BioMedical. John also spent 10 years at Tyco Healthcare/US Surgical and 4 years at Smith and Nephew Sports Medicine, all in senior sales management positions. John graduated with a BS in Marketing from Virginia Tech University. He lives in the Boston area.
Tom is a senior finance professional, having served as Chief Financial Officer and Company Secretary for a number of public companies, listed on the ASX and international stock exchanges (NASDAQ, TSX, NZSE) including most recently Simavita Ltd and Genetic Technologies Ltd. With considerable experience in the medical devices, technology and healthcare industries, Tom is responsible for all global finance functions at GKC and plays a critical role in capital raising activity.
Professor Malcolm Horne is a co-founder of GKC and co-developed the company’s lead product the PKG™. Concurrently, Professor Horne maintains roles at the Florey Institute of Neuroscience and Mental Health, as Professor of Neuroscience at University of Melbourne and manages a clinical practice in movement disorders at St Vincent’s Hospital, Melbourne. Previously, Professor Horne held key roles in brain disorder related medical associations including the President of the Parkinson’s Disease Association (1991-1993) and Deputy Chairman of the Australian Brain Foundation (1994-1997). Professor Horne’s field of research includes various aspects of Parkinson’s disease. As a recognised leader in Parkinson’s clinical practice and research, Professor Horne has over 200 publications.
Michelle has previously held senior roles within industry and Government, including extensive experience in policy and program design, and served for three years in various positions at the Australian Stem Cell Centre including Chief Operating Officer and Company Secretary, with specific responsibility for Business Development and Government Affairs. Michelle is a qualified lawyer and is based in Melbourne.
Global medical device reimbursement strategist Peter Lynch brings high value experience to GKC. A former Global Reimbursement Director at Medtronic, Peter has worked directly with a multitude of geographies including USA, Europe, Asia-Pacific, Latin America, MEA, China, India, Japan, & Australia. As Head of Global Market Access, Reimbursement and Health Economics, Peter plans and executes GKC’s reimbursement activities in different jurisdictions around the globe, seeking funding approvals from payers for the PKG™. Peter also drives payer-focused evidence development around the world to support the clinical and economic value of the PKG™. Peter is based in our USA office in Minneapolis.
Brendan has a background in medical device development projects ranging from software to electronic auto-injectors and disposables. He has held positions in the global headquarters of Merck KGaA’s medical device division as a Project Manager and later Associate Director of Reliability, Support & Maintenance overseeing the lifecycle management of a large device portfolio. Prior to this, Brendan held various consulting roles in pharma with Eli Lilly and Serono. Brendan is Dutch, and has worked for several years in Ireland and Switzerland prior to relocating to Australia.
Brooke brings over 25 years experience in the development of medical devices and has been deeply involved in the introduction of some of the most important product innovations in our industry, including the earliest advanced angioplasty balloons for use in interventional cardiology and the world’s first peripheral embolic protection device, Spyder, for which she received multiple patents for her work. It remains the industry standard to this day. Brooke also has extensive experience in China, where she has lead, as a consultant, GKCs entry strategy into this key market.